Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
6 search results for:

Bevacizumab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 02-25-2017 | Macular edema | Article

    Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema

    To evaluate the visual and anatomical outcomes following switching therapy from bevacizumab to aflibercept in patients with persistent diabetic

  2. 07-14-2022 | Retinopathy | News | Article
    News in brief

    ‘Step therapy’ compromise preserves good outcomes in diabetic macular edema

    Starting people on bevacizumab and switching to aflibercept only when necessary keeps costs down without compromising treatment efficacy for people with diabetic macular edema, shows a randomized trial.

    Author:
    Eleanor McDermid
    Published in:
    N Engl J Med 2022; doi:10.1056/NEJMoa2204225 N Engl J Med 2022; doi:10.1056/NEJMe2208454
  3. 05-09-2017 | Aflibercept | News | Article

    Anti-VEGF therapy can improve diabetic retinopathy

    The improvements were broadly similar with the three different anti-VEGF agents, although patients with proliferative diabetic retinopathy appeared to do better with aflibercept than with ranibizumab or bevacizumab.

    Published in:
    JAMA Ophthalmol 2017; Advance online publication
  4. 08-22-2017 | Retinopathy | Editorial | Article

    Antivascular endothelial growth factor treatment for proliferative diabetic retinopathy: Perspective on the CLARITY study

    Options for anti-VEGF treatment include the US Food and Drug Administration-approved regimens of ranibizumab or aflibercept or the off-label usage of bevacizumab.

    Author:
    Nathaniel B. Rieveschl, Felipe F. Conti, Rishi P. Singh
  5. 07-04-2017 | Complications | News | Article

    June Cochrane review round-up

    Another review – a network meta-analysis – compared the efficacy of the currently available anti-VEGF treatments for diabetic macular edema: aflibercept, bevacizumab, and ranibizumab.

    Published in:
    Cochrane Database Syst Rev 2017; 6 : CD010137, CD007419, CD009613, CD011979, CD011038
  6. 07-16-2015 | Retinopathy | Book chapter | Article

    A basic scientific understanding of diabetic retinopathy

    The central role of VEGF in the pathogenesis of DR is further supported by the successful clinical use of anti-VEGF agents such as bevacizumab, ranibizumab, and aflibercept for the treatment of diabetic macular edema [33].

    Author:
    Nathaniel Sears, Alex Yuan
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.